- Home
- CYBN
CYBN
Cybin Inc.
as 07-01-2024 4:00pm EST
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 270.5M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $0.74 | Next Earning Date: | 06-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cybin Inc. News
CYBN Breaking Stock News: Dive into CYBN Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
What Makes Cybin Inc. (CYBN) a New Buy Stock
Business Wire
6 days ago
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
Business Wire
13 days ago
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Zacks
21 days ago
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
Business Wire
21 days ago
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
Business Wire
a month ago
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
Business Wire
2 months ago
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
Business Wire
2 months ago
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
Share on Social Networks:
Disclaimer
The information presented on this page, "CYBN Cybin Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.